Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Podcast Summary

Introduction

Dr. Warrick Bishop, a cardiologist, author, and CEO of the Healthy Heart Network, hosts this episode focused on helping people understand cardiovascular health management. In this episode, Dr. Bishop addresses several specialized and less commonly discussed topics in cholesterol and heart health management, including ketogenic diets, cholesterol management in women, and treatment considerations for specific patient populations.

Key Takeaways

• Ketogenic and very low-carbohydrate diets can effectively flatten blood sugar levels, reduce appetite, promote weight loss, lower blood pressure, and improve insulin control, leading to better overall health outcomes and improved mood stability.

• A major concern with ketogenic diets is that they often involve replacing carbohydrates with saturated fats, which can significantly elevate LDL cholesterol levels—particularly in "hyper responders"—and potentially increase cardiovascular risk despite other positive health improvements.

• Even though some patients on keto diets show large, fluffy LDL particles (considered less harmful), high LDL particle numbers can still lead to arterial plaque buildup, as evidenced by young people with familial hypercholesterolemia developing plaque despite favorable particle characteristics.

• Dr. Bishop recommends a cautious approach for high-risk or secondary prevention patients on keto diets: maintain reduced carbohydrate intake but minimize saturated fat consumption and aim for the lowest possible LDL cholesterol targets.

• Substantial research confirms that women benefit significantly from statin therapy for both all-cause mortality and cardiovascular-related mortality, contrary to historical uncertainty in this area.

• Women also benefit from non-statin cholesterol-lowering medications, and hormone replacement therapy is considered potentially beneficial for perimenopausal women without increasing cardiovascular disease risk.

• Pregnant women should avoid cholesterol-lowering medications due to insufficient safety data, requiring careful planning when young women with familial hypercholesterolemia wish to become pregnant.

• Older populations (beyond age 65-70) represent the highest cardiovascular risk group and are suitable candidates for cholesterol-lowering therapy when patients are willing and in either primary or secondary prevention settings.

• Chronic renal disease is a very high cardiovascular risk indicator, and while statin use is unclear for dialysis patients, those awaiting transplants should receive cholesterol-lowering therapy to protect their vasculature.

• Transplant patients (heart, lung, or kidney) generally require specialist-directed LDL cholesterol-lowering therapy, with careful attention to drug interactions between transplant medications and statins that may be metabolized through similar pathways.